Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double‐blind trial
Jinlin Hou, You‐Kuan Yin, Daozhen Xu, Deming Tan, Junqi Niu, Xiaqiu Zhou, Yuming Wang, Limin Zhu, Yongwen He, Hong Ren, Mobin Wan, Chengwei Chen, Shanming Wu, Yagang Chen, Jiazhang Xu, Qinhuan Wang, Lai Wei, George Chao, Barbara Fielman Constance, George Harb, Nathaniel A. Brown, Jidong Jia – 26 January 2008 – Chronic hepatitis B and its life‐threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease.